On May 2, 2018, Concordia International Corp. announced that Graeme Duncan has been appointed interim Chief Executive Officer of the company, effective immediately. Mr. Duncan will succeed Concordia's current Chief Executive Officer, Allan Oberman, who is leaving the company to pursue other opportunities.

As previously announced, Mr. Duncan was scheduled to depart Concordia on June 30, 2018. Mr. Duncan will now be staying on with the company and will assume leadership as interim Chief Executive Officer while Concordia works to complete its CBCA Proceedings and the realignment of its capital structure. Mr. Duncan served as President of Concordia's International segment since January 2016.

Prior to his role as President, he was Managing Director for Concordia's International segment. The company also announced that its Chief Corporate Development Officer, Sarwar Islam, is leaving the company to pursue other opportunities, effective immediately. Guy Clark, previously Chief Strategy Officer at AMCo Pharmaceuticals from 2013 to 2015, will join Concordia, effective May 3, 2018, as the company's Chief Corporate Development Officer.

Mr. Clark brings to Concordia more than 25 years of experience in the pharmaceutical industry, including previous senior roles at Glenmark Pharmaceuticals and IVAX Pharmaceuticals. Mr. Clark also brings with him proven pipeline development and corporate expansion experience.